Introduction
In past years the prostaglandin (PG)-synthesizing enzyme cyclooxygenase-2 (COX-2) has been implied to confer tumor-promoting properties (Gupta and DuBois, 2001) . Therefore, inhibition of COX-2 has been recognized as a strategy for cancer prevention or treatment. Population-based studies associating chronic intake of nonsteroidal antiinflammatory drugs (NSAIDs) with a 40-50% reduction in the relative risk of death by colon cancer (Gupta and DuBois, 2001 ) as well as clinical evidence demonstrating a modest reduction of colorectal polyps by the COX-2 inhibitor celecoxib (Steinbach et al., 2000) are apparently in line with this concept. However, preclinical data showing antiproliferative and proapoptotic properties of NSAIDs and COX-2 inhibitors were frequently derived from experiments using suprapharmacological concentrations of these drugs. More importantly, however, these substances retained their proapoptotic properties in cells lacking COX-2 (Zhang et al., 1999; Hwang et al., 2002; Denkert et al., 2003) .
In addition to these concerns, increasing evidence suggest that induction of COX-2 does not necessarily contribute to tumor cell survival or tolerance to proapoptotic insult. Thus, overexpression of COX-2 decreased proliferation and increased apoptosis of endothelial (Narko et al., 1997) and osteosarcoma cells (Xu et al., 2006) . Moreover, R( þ )-methanandamide, a stable analogue of the endocannabinoid anandamide, was recently shown to induce apoptosis of neuroglioma cells via a COX-2-dependent mechanism (Hinz et al., 2004; Eichele et al., 2006) . Further evidence supporting the involvement of COX-2-derived PGs in proapoptotic and cytotoxic effects of diverse other substances was provided by studies performed on human leukemia (Chen et al., 2005) , C6 rat glioma (Maccarrone et al., 2002) , colorectal carcinoma (Dommels et al., 2003) and H-ras-transformed breast epithelial cells (Na et al., 2005) .
Despite the well-described proapoptotic function of COX-2 in these systems, the mechanism by which COX-2 elicits cell death is still poorly defined. In this context, PGs of the D 2 and J 2 series are of special interest, referring to their known ability to regulate cell proliferation and death (Na and Surh, 2003) , partly involving activation of the peroxisome
Results
Influence of paclitaxel, cisplatin and 5-FU on the expression and activity of COX-2 in HeLa cells In a first set of experiments, the impact of the chemotherapeutics on COX-2 expression by HeLa cells was investigated. For all three compounds, a timedependent prolonged increase at the transcriptional level could be observed ( Figure 1a ) that was accompanied by increased COX-2 protein levels ( Figure 1b) . Accordingly, either chemotherapeutic upregulated COX-2 protein synthesis in a concentration-dependent manner (Figure 1b) . In parallel with elevated COX-2 expression, PG production was significantly increased. This applies for both PGs assessed, PGE 2 which is the major COX-2 product as well as PGD 2 , which was recently shown to be involved in apoptosis induction of different tumor cells (Chen et al., 2005; Kim et al., 2005) . As PGE 2 is the major product, basal concentrations in supernatants of untreated cells were much higher (310.8 nM ± 28.9 nM) as compared to PGD 2 levels (94.5 pM±10.6 pM). Levels of 15-deoxy-D 12,14 -PGJ 2 (15d-PGJ 2 ), a dehydration metabolite of PGD 2 , were not detectable when using a commercially available ELISA assay (Assay Designs Inc., Ann Arbor, MI, USA) with a limit of quantification of 36.8 pg ml À1 (0.116 nM; data not shown). Inhibition of COX-2 activity by NS-398 at a concentration of 1 mM completely abrogated PGE 2 and PGD 2 synthesis stimulated by either chemotherapeutic (Figure 1c) .
Influence of paclitaxel, cisplatin and 5-FU on apoptosis of HeLa cells Analysis of cytotoxicity by Trypan blue staining revealed a time-and concentration-dependent cytotoxic effect of paclitaxel, cisplatin and 5-FU on HeLa cells ( Figure 2 ). As this study was designed to investigate mechanisms of apoptosis induction, we next evaluated whether measured toxicity was a result of apoptotic cell death. Therefore, cytoplasmic histone-associated DNA fragments were analysed. As shown in Figure 2 , the investigated chemotherapeutics led to significantly increased cytoplasmic levels of DNA fragments following a 24-h incubation period, reaching a maximum after 48 h.
Influence of COX-2 siRNA on paclitaxel-, cisplatin-and 5-FU-induced apoptosis The main emphasis of the present study was the question whether COX-2 contributes to paclitaxel-, cisplatin-and 5-FU-induced cell death. To address this issue, a set of experiments using small-interfering RNA (siRNA) targeting COX-2 was performed. As shown in
Figures 3a-c, transfection of cells with COX-2 siRNA significantly inhibited apoptosis and toxicity elicited by either chemotherapeutic. At the concentration tested, COX-2 siRNA was shown to interfere with paclitaxel-, cisplatin-and 5-FU-induced COX-2 protein expression (Figures 3a-c) . COX-2 siRNA alone had no effect on either apoptosis, toxicity but suppressed basal COX-2 protein expression (Figure 3d) . Likewise, control experiments revealed no significant effect of nonsilencing siRNA on all chemotherapeutic-modulated parameters investigated (Figures 3a-d) .
Influence of NS-398 on paclitaxel-, cisplatin-and 5-FUinduced apoptosis To confirm the decisive role of COX-2 in chemotherapeutics-induced apoptosis, additional COX-2 inhibitor experiments were performed in HeLa cells. To this end, COX-2 activity was abolished using the selective COX-2 inhibitor NS-398 at a concentration of 1 mM, which was sufficient to abrogate PG synthesis ( Figure 1c ). As shown in Figures 4a-c, co-incubation of chemotherapeutics with NS-398 significantly protected HeLa cells against DNA fragmentation and cytotoxicity. On the other hand, incubation of cells with NS-398 (1 mM) alone had no significant effect on both parameters (Figure 4d ). In contrast, higher concentrations of NS-398 (30-50 mM) caused significant DNA fragmentation and cytotoxicity ( Figure 4d ). Experiments assessing the activity of the key apoptosis enzyme caspase-3 additionally supported the role of COX-2 in apoptosis induction as incubation with NS-398 significantly reduced caspase-3 activity induced by either chemotherapeutic (Figure 4e ).
Influence of exogenous PGs on HeLa cell apoptosis
To clarify the mechanisms by which COX-2 upregulation contributes to apoptosis, we evaluated the impact of exogenously added COX-2-derived PGs on apoptotic cell death. As summarized in Figure 5a , PGD 2 and 15d-PGJ 2 induced DNA fragmentation in a concentration-dependent manner. PGE 2 on the other hand did not elicit apoptosis (Figure 5a ).
Role of L-PGDS in paclitaxel-, cisplatin-and 5-FUinduced apoptosis Apparently, COX-2-dependent products generated by the enzymatic activity of L-PGDS elicit apoptosis. We therefore decided to confirm the role of this enzyme in chemotherapeutics-induced apoptosis using further siRNA approaches. As shown in Figures 5b-d , transfection of cells with L-PGDS siRNA significantly inhibited apoptosis elicited by the chemotherapeutic agents. At the concentration tested, L-PGDS siRNA was shown to inhibit basal L-PGDS protein expression (Figure 5f ). In contrast to COX-2, which was induced by either chemotherapeutic, L-PGDS levels were not altered by these compounds. Control experiments with sole L-PGDS siRNA treatment revealed no effect on DNA fragmentation (Figure 5e ). Likewise, a nonsilencing siRNA being used as a negative control had no effect on all parameters investigated (Figures 5e and f) . Role of PPARg in PG-induced apoptosis of HeLa cells As an endogenous ligand of PPARg, 15d-PGJ 2 is likely to exert its biologic effects via this receptor. For it was recently shown that PGD 2 itself might also act as ligand for PPARg (Kim et al., 2005) , we consequently assessed the role of PPARg in apoptosis induction of PGD 2 and 15d-PGJ 2 to further shed light on the mechanisms underlying COX-2-dependent apoptosis. Once again we used siRNA to effectively knock down PPARg, which was demonstrated by Western blot analysis of the receptor protein ( Figure 6b ). As suspected, PPARg siRNA-transfected HeLa cells were significantly less sensitive to apoptosis elicited by both PGs (Figure 6a ) with PPARg siRNA alone having no effect on DNA fragmentation ( Figure 7d ). A comparable protection was also seen when PG-treated cells were co-incubated with a PPARg antagonist (GW-9662) ( Figure 6e ). Moreover, induction of apoptosis as well as inhibition of apoptosis by PPARg siRNA was mimicked in presence of the synthetic PPARg agonist troglitazone (Figures 6c and d ).
Role of PPARg in chemotherapeutics-induced apoptosis of HeLa cells
The observation of a PPARg-dependent apoptosis induction through exogenous PGs encouraged us to assess the investigated chemotherapeutics for a similar mechanism. Thus, additional PPARg knockdown experiments were performed. As shown in Figure 7 , 
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Figure 3 Effect of cyclooxygenase-2 (COX-2) small-interfering RNA (siRNA) on chemotherapeutics-induced apoptosis of HeLa cells. Effect of COX-2 siRNA and nonsilencing siRNA on cytotoxicity, DNA fragmentation and COX-2 protein expression in the presence of (a) paclitaxel, (b) cisplatin (c) 5-fluorouracil (5-FU) and (d) in the absence of test compounds. Cells were incubated with the respective compounds at the indicated concentrations or its vehicles for 24 h (Western blots) and 48 h (cytotoxicity, DNA fragmentation), respectively. Transfection with COX-2 siRNA (2.5 mg ml
À1
) or nonsilencing siRNA (non-sil. siRNA; 2.5 mg ml
) was performed 24 h prior to addition of test compounds to the cells. (Figure 7e ). Further experiments substantiated these findings by antagonizing PPARg with GW-9662, which as well attenuated apoptosis induced by either chemotherapeutic (Figure 7f ).
Involvement of COX-2 in chemotherapeutics-induced apoptosis in A549 and C33A cells The above-described findings might be of clinical significance if they were not restricted to one single cell line. Therefore, we repeated the key experiments in a cell line derived from human lung cancer (A549) as well as in another cervical carcinoma cell line (C33A). As shown in Figure 8a , COX-2 expression was increased in both cell lines after treatment with paclitaxel, cisplatin and 5-FU. Exogenous PGD 2 and 15d-PGJ 2 induced DNA fragmentation, PGE 2 however failed to induce apoptosis. Apoptosis induction after chemotherapeutic treatment again proved to be sensitive to NS-398 co-incubation (Figures 8b and c) .
Discussion
Our results clearly demonstrate a COX-2-dependent mechanism underlying the proapoptotic action of the chemotherapeutics paclitaxel, cisplatin and 5-FU. Indeed, each of these compounds led to a profound induction of COX-2 expression and activity. This in turn Cyclooxygenase-2 mediates cancer cell apoptosis K Eichele et al led to an increased synthesis of PGE 2 and PGD 2 , which was sensitive to the selective inhibitor of COX-2 activity, NS-398. As NS-398 reduced PG levels below controls, it is likely that COX-2 is active at a basal rate in HeLa cells. Indeed, COX-2 protein was detectable in untreated HeLa cells as well, albeit at a very low level. COX-2 activity increased by either chemotherapeutic was accompanied by a substantial decrease of cellular viability and enhanced accumulation of cytoplasmic DNA fragments, which proved to be the result of COX-2 activity, rather than a concomitant phenomenon. Thus, knockdown or inhibition of COX-2 desensitized HeLa Cyclooxygenase-2 mediates cancer cell apoptosis K Eichele et al cells to toxicity by either drug. Moreover, NS-398 interfered with apoptosis induction in additionally assessed cell lines, derived from cervical (C33A) and lung carcinoma (A549). In fact, each of the investigated chemotherapeutics induced COX-2 protein expression in these cells. However, for all cell lines, paclitaxelinduced apoptotic death was inhibited to a moderate extend only. It is obvious, that COX-2 plays a partial role and independent mechanisms comparably contribute to the apoptotic response after paclitaxel treatment. The reason for these findings remain speculative, but they may be related to the fact that paclitaxel mainly interferes with cell division, whereas cisplatin and 5-FU affect DNA synthesis. Hence, it would be overestimating to propose COX-2 as a key mediator in the apoptotic response to any chemotherapeutic. Nevertheless, with reference to the fact that in humans peak plasma concentrations of 4.5 mM ), the effects of paclitaxel on COX-2 induction and subsequent apoptotic cell death were observed at very low, therapeutically relevant concentrations. Regarding cisplatin and 5-FU, the applied concentrations slightly exceed peak plasma levels, yet these concentrations are quite common in vitro. Therefore, these results are suspected to be of clinical significance.
Looking for the targets conferring COX-2-induced apoptosis, our further interest has focused on diverse PGs synthesized upon COX-2 stimulation. In this context, PGD 2 and its dehydration product 15d-PGJ 2 were both shown to elicit apoptosis in HeLa, A549 and C33A cells at concentrations slightly below the range of those frequently applied in cell culture experiments (Chen et al., 2005) . On the other hand, PGE 2 , which was recently proven to cause apoptosis of H4 neuroglioma cells (Hinz et al., 2004) and primary cultures of glioblastoma multiforme (Lalier et al., 2007) , was virtually inactive in altering DNA fragmentation in these cell lines. Nevertheless, it has to be pointed out that the applied concentrations of exogenous PGD 2 exceeded those measured in cell culture supernatants after treatment with chemotherapeutics. This discrepancy might be due to the intermediate position of PGD 2 in PG turnover and its chemical instability. Our results implying a contribution of PGD 2 to chemotherapeutic-induced apoptosis were further substantiated by using siRNA targeting its biosynthesizing enzyme L-PGDS, which catalyses the conversion of PGH 2 to PGD 2 . As knockdown of L-PGDS significantly interfered with apoptosis induction by the investigated chemotherapeutics, it seems very likely that L-PGDS via generation of PGD 2 is a key mediator in this process.
Given that activation of PPARg by 15d-PGJ 2 and PGD 2 has been implicated in antiproliferation and apoptosis of several cancer cells (Clay et al., 1999; Kim et al., 2005; Shen et al., 2005) , we next analysed the importance of this transcription factor in eliciting chemotherapeutics-induced cell death. The anticancer properties of PPARg activators, especially of 15d-PGJ 2 , are associated with their capability to regulate the expression of a wide array of genes involved in controlling cell cycle arrest and apoptosis, including cyclin-dependent kinase inhibitor p21 waf/cip1 , caspase-3, -4 and -8. In addition, Bcl-2 family members like Bax and Bcl-2 are affected as well as an elevation of p53 levels and activity (for review see Na and Surh, 2003) . In our hands, PGD 2 -and 15d-PGJ 2 -induced DNA fragmentation were inhibited by knockdown of PPARg by siRNA or by co-incubation with the PPARg antagonist, GW-9662, suggesting an involvement of PPARg activation in apoptosis by these COX-2 products in HeLa cells. That a similar mechanism subsequent to COX-2 induction may also account for the investigated chemotherapeutics is supported by our finding that apoptosis elicited by paclitaxel, cisplatin or 5-FU was likewise impaired when PPARg was knocked down or blocked. Finally, troglitazone, a PPARg agonist with an about 10-fold lower affinity than 15d-PGJ 2 (Chen et al., 2004) , mimicked the apoptotic response of PGD 2 , 15d-PGJ 2 and chemotherapeutics in HeLa cells. These results suggest that COX-2-dependently synthesized PGD 2 activates PPARg and thereby induces apoptosis. However, PPARg can as well be activated by numerous naturally occurring fatty acids with preference for polyunsaturated fatty acids like linoleic acid and arachidonic acid. Whether these ligands might play a role in chemotherapeutic treatment has not been established yet. Additional experiments will have to be performed to help understanding PPARg-linked processes in anticancer therapy.
Concerning current concepts in pharmacology, the results of the present study raise one important question. In fact, overexpression of COX-2 has been implicated in resistance to apoptosis, proliferation and angiogenesis (Tsujii and DuBois, 1995) and was considered to unfavorably alter the response of malignant cells to cytotoxic therapy. This fact led to the hypothesis that anticancer effects might be increased by COX-2 inhibition (Altorki et al., 2003) , and was supported by several clinical evidence, which, however, often refer to historical controls and therefore lack reliability (Nugent et al., 2005; Argiris et al., 2006) . By contrast, several clinical trials suggested that inhibition of COX-2 by celecoxib does not improve clinical outcome (Csiki et al., 2005; Pan et al., 2005) . Finally, the dosage of celecoxib (400 mg b.i.d.) during most clinical trials focusing on its anticancer properties was two-to fourfold as high as dosages required for treatment of osteoarthritis (100 mg b.i.d.) and rheumatoid arthritis (200 mg b.i.d.), respectively. The same applies to preclinical in vitro studies using suprapharmacological concentration of these drugs (Zhang et al., 1999; Hwang et al., 2002; Denkert et al., 2003) , suggesting that the anticancer activity of these compounds reflects COX-independent effects. In our hands, only higher concentrations of NS-398 (that is, 30-50 mM), which are far above the concentration needed for full inhibition of PG synthesis, elicited a significant proapoptotic and cytotoxic response. Noteworthy, in our study NS-398 significantly interfered with the proapoptotic and cytotoxic action of either chemotherapeutic at a concentration of 1 mM, which itself did not induce apoptosis or cell death, but completely inhibited chemotherapeutics-induced PGD 2 synthesis.
Overall, our results imply that under certain circumstances COX-2 might promote tumor cell death and that concurrent inhibition of COX-2 could therefore diminish the efficacy of COX-2-inducing chemotherapeutic drugs. This finding might be of clinical significance given that COX-2 inhibitors are frequently used during chemotherapy for pain reduction, and are recently discussed as supportive anticancer agents. Moreover, our data provides evidence for a direct contribution of L-PGDS and PPARg activity to COX-2-mediated apoptosis induction after chemotherapeutics treatment and therefore suggests L-PGDS and PPARg as promising molecular targets for the development of novel chemotherapeutic agents.
Materials and methods

Materials
Paclitaxel, cisplatin (cis-diamine-dichloroplatinum(II)), 5-FU and GW-9662 were obtained from Sigma-Aldrich Chemie (Steinheim, Germany), NS-398 from Alexis Deutschland GmbH (Gru¨nberg, Germany), PGE 2 was from Cayman (Ann Arbor, MI, USA), PGD 2 and 15d-PGJ 2 were from Calbiochem (Darmstadt, Germany). Dulbecco's modified Eagle's medium (DMEM) with 4 mM L-glutamine and 4.5 g l À1 glucose was from Cambrex Bio Science Verviers S.p.r.l. (Verviers, Belgium). Fetal calf serum and penicillinstreptomycin were obtained from PAN Biotech (Aidenbach, Germany) and Invitrogen (Karlsruhe, Germany), respectively.
Cell culture
HeLa, C33A (human cervical carcinoma) and A549 (human lung carcinoma) cells were maintained in DMEM supplemented with 10% heat-inactivated fetal calf serum, 100 U ml À1 penicillin and 100 mg ml À1 streptomycin. The cells were grown in a humidified incubator at 37 1C and 5% CO 2 . All incubations were performed in serum-free medium.
Quantitative RT-PCR analysis HeLa cells were grown to confluence in 24-well plates. Following incubation of cells with the respective test compounds or vehicle for the indicated times, supernatants were removed and cells were lysed for subsequent RNA isolation. Total RNA was isolated using the RNeasy total RNA Kit (Qiagen, Hilden, Germany). b-Actin-(internal standard) and COX-2 mRNA levels were determined by quantitative realtime RT-PCR as described recently (Ramer et al., 2003) .
Western blot analysis
Cells grown to confluence in 10-cm dishes or six-well cell culture plates were incubated with test substance or vehicle for the indicated times. Proteins were isolated and analysed as described recently (Hinz et al., 2004) . Commercially available specific antibodies raised to COX-2 (BD Biosciences, Heidelberg, Germany), PPARg (Cayman) and L-PGDS (Cayman) as well as horseradish peroxidase-conjugated Fab-specific antimouse immunoglobulin G (IgG) (for COX-2 Western blots; New England BioLabs, Frankfurt, Germany) and anti-rabbit IgG (New England BioLabs) were used.
Determination of PGs
HeLa cells seeded in 24-well plates at a density of 5 Â 100 000 cells per well were grown to confluence. Thereafter, cells were incubated with the respective test compounds or its vehicles for the indicated times in 300 ml culture medium without serum. PGE 2 and PGD 2 concentrations in cell culture supernatants were determined using commercially available enzyme immunoassay kits (Cayman). The PGD 2 enzyme assay is based on the conversion of PGD 2 to a stable methoxylamine (MOX) derivative. Treatment of the sample with MOX hydrochloride (MOX-HCl) converts PGD 2 into PGD 2 -MOX, preventing its further chemical degradation following collection of supernatants.
Cytotoxicity analysis
HeLa cells were seeded in 24-well plates at a density of 1 Â 100 000 cells per well and were grown to confluence. Thereafter, cells were incubated with the respective test compounds for the indicated times in 500 ml medium without serum. Following the desired incubation time, cytotoxicity was measured by Trypan blue staining. Namely, a freshly prepared solution of 100 ml Trypan blue (0.1%) was mixed to 100 ml of cell suspension during 1 min, spread onto a Neubauercounting chamber and covered with a coverslip. Nonviable cells were blue stained. At least 100 cells were counted per treatment. Cytotoxicity was calculated as the ratio of the number of Trypan blue positive cells to total cell number.
Detection of DNA fragmentation HeLa cells were seeded in 24-well plates at a density of 1 Â 100 000 cells per well and were grown to confluence. Thereafter, cells were incubated with the respective test compounds or its vehicles for the indicated times. For apoptosis detection, adherent cells were harvested by trypsinization and combined with detached cells. Cytoplasmic histone-associated DNA fragments (mono-and oligonucleosomes) were assessed using the cell death detection ELISA PLUS kit (Roche Diagnostics, Mannheim, Germany).
Detection of caspase-3 activity HeLa cells were seeded in 24-well plates at a density of 1 Â 500 000 cells per well and grown for 24 h. Thereafter, cells were incubated with the respective test compounds or its vehicles for the indicated times. Adherent cells were harvested by trypsinization and combined with detached cells. Caspase-3 activity was assessed using the caspase-3 colorimetric assay kit (Sigma-Aldrich Chemie, Steinheim, Germany).
Construction of siRNA siRNA against COX-2 was synthesized by Qiagen. The target sequence was 5 0 -AACTGCTCAACACCGGAATTT-3 0 (bases 291-311 of NM000963.1). The siRNA sequence was controlled via BLAST search and did not show any homology to other known human genes. siRNA targeted against L-PGDS (target sequence 5 0 -CACAATAAACTCCGGAAGCAA-3 0 ) and PPARg (target sequence 5 0 -GAGGGCGATCTTGACAGGAAA-3 0 ) were commercially available (Qiagen). A negative (nonsilencing) control siRNA was purchased from Eurogentec (Seraing, Belgium; catalog no. OR-0030-neg).
Transfections
Cells were seeded into 24-well plates and grown to 50-80% confluence. Thereafter, cells were transfected with the respective silencing siRNA or nonsilencing siRNA using RNAiFect (Qiagen) as described recently (Hinz et al., 2004) . The final concentration of siRNA or nonsilencing siRNA was 2.5 mg ml À1 (COX-2 siRNA) and 1.25 mg ml À1 (L-PGDS siRNA and PPARg siRNA), respectively.
Statistics
All statistical analyses were undertaken using GraphPad Prism 4.01. (GraphPad Software, San Diego, CA, USA).
Abbreviations
COX-2, cyclooxygenase-2; 5-FU, 5-fluorouracil; L-PGDS, lipocalin-type prostaglandin D synthase; NSAID, nonsteroidal antiinflammatory drug; PG, prostaglandin; PPARg, peroxisome proliferator-activated receptor g; siRNA, small-interfering RNA.
